Lometraline

Lometraline
Clinical data
Other names	N,N-dimethyl-8-chloro-5-methoxy-1-aminotetralin
ATC code	None;
Identifiers
	IUPAC name 8-chloro-5-methoxy-N,N-dimethyl-1,2,3,4-tetrahydro-1-naphthalenamine;
CAS Number	39951-65-0 ; 34552-78-8 (hydrochloride);
PubChem CID	34789 ;
ChemSpider	32014 ;
UNII	V78B234QEY ;
KEGG	D02669 ;
ChEMBL	ChEMBL2111119 ;
CompTox Dashboard (EPA)	DTXSID70865981 ;
Chemical and physical data
Formula	C13H18ClNO
Molar mass	239.74 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES Clc1ccc(OC)c2c1C(N(C)C)CCC2;
	InChI InChI=1S/C13H18ClNO/c1-15(2)11-6-4-5-9-12(16-3)8-7-10(14)13(9)11/h7-8,11H,4-6H2,1-3H3; Key:MTWNWMGGMZUIMZ-UHFFFAOYSA-N;

Last updated September 20, 2025

Lometraline (INN; developmental code name CP-14,368) is a drug and an aminotetralin derivative.^[1] A structural modification of tricyclic neuroleptics, lometraline was originally patented by Pfizer as an antipsychotic, tranquilizer, and antiparkinsonian agent.^[2]^[3] However, it was instead later studied as a potential antidepressant and/or anxiolytic agent, though clinical studies revealed no psychoactivity at the doses used and further investigation was suspended.^[1]^[4]^[5] Further experimental modifications of the chemical structure of lometraline resulted in the discovery of tametraline, a potent inhibitor of the reuptake of dopamine and norepinephrine, which in turn led to the discovery of the antidepressant sertraline, a selective serotonin reuptake inhibitor (SSRI).^[6]

References

1 2 Park S, Gershon S, Angrist B, Floyd A (February 1972). "Evaluation of an aminotetraline, CP 14.368, as an antidepressant". Current Therapeutic Research, Clinical and Experimental. 14 (2): 65–70. PMID 4401233.
↑ Drake E (27 January 1994). Saunders pharmaceutical word book, 1994. W.B. Saunders Co. ISBN 978-0-7216-5254-2 . Retrieved 27 April 2012.
↑ United States. Patent Office (1972). "Lometraline: tranquillizer, anti-parkinson agent". Official gazette of the United States Patent Office: Patents. The Office. Retrieved 27 April 2012.
↑ McMahon FG (1974). Psychopharmacological agents. Futura Pub. Co. ISBN 978-0-87993-052-3 . Retrieved 27 April 2012.
↑ Bayerische Julius-Maximilians-Universität Würzburg. Arbeitskreis für Schlafforschung (1973). The Nature of sleep. Die Natur des Schlafes. La nature du sommeil: International symposium, Würzburg, 23-26.9.1971. G. Fischer. ISBN 978-3-437-10295-0 . Retrieved 27 April 2012.
↑ Koe BK, Harbert CA, Sarges R, Weissman A, Welch WM (2006). "Discovery of sertraline (Zoloft®)". Archived from the original on 2014-12-30. Retrieved 2012-04-27.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[pmid4401233-1] 1 2 Park S, Gershon S, Angrist B, Floyd A (February 1972). "Evaluation of an aminotetraline, CP 14.368, as an antidepressant". Current Therapeutic Research, Clinical and Experimental. 14 (2): 65–70. PMID 4401233.

[DrakeCompany1994-2] Drake E (27 January 1994). Saunders pharmaceutical word book, 1994. W.B. Saunders Co. ISBN 978-0-7216-5254-2 . Retrieved 27 April 2012.

[Office1972-3] United States. Patent Office (1972). "Lometraline: tranquillizer, anti-parkinson agent". Official gazette of the United States Patent Office: Patents. The Office. Retrieved 27 April 2012.

[McMahon1974-4] McMahon FG (1974). Psychopharmacological agents. Futura Pub. Co. ISBN 978-0-87993-052-3 . Retrieved 27 April 2012.

[Schlafforschung1973-5] Bayerische Julius-Maximilians-Universität Würzburg. Arbeitskreis für Schlafforschung (1973). The Nature of sleep. Die Natur des Schlafes. La nature du sommeil: International symposium, Würzburg, 23-26.9.1971. G. Fischer. ISBN 978-3-437-10295-0 . Retrieved 27 April 2012.

[Pfizer2006-6] Koe BK, Harbert CA, Sarges R, Weissman A, Welch WM (2006). "Discovery of sertraline (Zoloft®)". Archived from the original on 2014-12-30. Retrieved 2012-04-27.

[1]

[2]

[3]

[4]

[5]

[6]